Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances
International Journal of Molecular Sciences · 13.06.2023 · 24 (12) · 10095
DOI: 10.3390/ijms241210095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.06.2023. Verfasst von Faryal Munir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Neoplasms, Second Primary, Leukemia. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hodgkin lymphoma, a hematological malignancy of lymphoid origin that typically arises from germinal-center B cells, has an excellent overall prognosis. However, the treatment of patients who relapse or develop resistant disease still poses a substantial clinical and research challenge, even though current risk-adapted and response-based treatment techniques produce overall survival rates of over 95%. The appearance of late malignancies after the successful cure of primary or relapsed disease continues to be a major concern, mostly because of high survival rates. Particularly in pediatric HL patients, the chance of developing secondary leukemia is manifold compared to that in the general pediatric population, and the prognosis for patients with secondary leukemia is much worse than that for patients with other hematological malignancies. Therefore, it is crucial to develop clinically useful biomarkers to stratify patients according to their risk of late malignancies and determine which require intense treatment regimens to maintain the ideal balance between maximizing survival rates and avoiding late consequences. In this article, we review HL’s epidemiology, risk factors, staging, molecular and genetic biomarkers, and treatments for children and adults, as well as treatment-related adverse events and the late development of secondary malignancies in patients with the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Pediatric Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- CARTOX Program, Department of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Pediatrics-Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Faryal Munir, Irtiza N Sheikh, Jiasen He, Priti Tewari, Sajad Khazal
Zitieren
APA
Munir, F., Hardit, V., Sheikh, I. N., AlQahtani, S., He, J., Cuglievan, B., Hosing, C., Tewari, P., & Khazal, S. (2023). Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances. International Journal of Molecular Sciences, 24(12), 10095. https://doi.org/10.3390/ijms241210095
Vancouver
Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B, et al. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances. International Journal of Molecular Sciences. 2023;24(12):10095. doi:10.3390/ijms241210095
BibTeX
@article{Munir2023,
author = {Munir, Faryal and Hardit, Viney and Sheikh, Irtiza N and AlQahtani, Shaikha and He, Jiasen and Cuglievan, Branko and Hosing, Chitra and Tewari, Priti and Khazal, Sajad},
title = {Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {12},
pages = {10095},
doi = {10.3390/ijms241210095}
}
EUVIMED